Hereditary Hemorrhagic Telangiectasia (HHT)
Conditions
Keywords
hereditary hemorrhagic telangiectasia, HHT, Osler-Weber-Rendu, pomalidomide, PATH-HHT, PATH-HHT ATLAS
Brief summary
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinical trial participants following completion of the double-blind, placebo-controlled study.
Detailed description
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant condition characterized by disordered angiogenesis that affects 1 in 5,000 people. It results in numerous clinical complications including severe recurrent epistaxis, gastrointestinal bleeding, chronic iron deficiency anemia (and possible transfusion dependence), high-output cardiac failure, and many others. In recognition that elevated levels of vascular endothelial growth factor (VEGF) are elevated in HHT, anti-angiogenic drugs are now being used to treat HHT off-label to manage HHT-associated bleeding. A primary agent used for this purpose is pomalidomide, an oral immunomodulatory drug with antiangiogenic properties. Pomalidomide was demonstrated to be efficacious over a 6-month treatment period in the multicenter U.S. randomized controlled PATH-HHT Study. The present study is the successor to PATH-HHT, the PATH-HHT ATLAS (After Trial Longitudinal Assessment Study). This study will evaluate the long-term impact of pomalidomide on epistaxis (as measured by the validated ESS, epistaxis severity score), gastrointestinal bleeding, and iron deficiency anemia (as assessed by hemoglobin measurements, red blood cell transfusions, and intravenous iron infusions).
Interventions
DRUGPomalidomide
Oral pomalidomide up to 4 mg daily
Sponsors
Massachusetts General Hospital
The Cleveland Clinic
University of North Carolina, Chapel Hill
University of California, San Francisco
Mayo Clinic
University of Utah
University of California, San Diego
University of Florida
Medical College of Wisconsin
Johns Hopkins University
University of Pennsylvania
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. A clinical diagnosis of HHT as defined by the Curacao criteria 2. Age \> 18 years 3. Platelet count ≥ 100 x 109/L prior to pomalidomide initiation 4. WBC ≥ 2.5 x 109/L prior to pomalidomide initiation 5. INR ≤ 1.4 and normal ± 2 sec activated partial thromboplastin time (aPTT) by local laboratory criteria (except for patients on a stable dose of warfarin or direct oral anticoagulants) 6. Epistaxis severity score ≥ 3 measured over the preceding month 7. A requirement for anemia, as determined by local laboratory normal ranges, and/or parenteral infusion of at least 250 mg of iron or transfusion of 1 unit of blood over the 24 weeks preceding the screening visit 8. All study participants must agree to be registered into the FDA mandated POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program 9. Females of childbearing potential (FCBP)† must adhere to the pregnancy testing schedule mandated by the POMALYST REMS program 10. Prior enrollment on PATH-HHT study (NCT03910244) * A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Exclusion criteria
1. Women currently breast feeding or pregnant 2. Renal insufficiency, serum creatinine \> 2.0 mg/dl 3. Hepatic insufficiency, bilirubin \> 2.0 (or \>4.0 in the setting of a prior clinical or genetic diagnosis of Gilbert's syndrome) or transaminases \> 3.0x normal 4. Prior treatment with thalidomide or other non-pomalidomide immunomodulatory imide drugs (IMiDs) within previous 6 months 5. Prior treatment with bevacizumab (systemic or nasal) within previous 6 weeks 6. Prior treatment with pazopanib within previous 6 weeks 7. The use of octreotide or estrogens within the previous month 8. History of prior unprovoked thromboembolism confirmed by venous ultrasound or other imaging modalities 9. Known peripheral neuropathy, confirmed by neurologic consultation 10. Known underlying hypoproliferative anemia (i.e. myelodysplasia, aplastic anemia) 11. Currently enrolled in other drug trials 12. Known hypersensitivity to thalidomide or lenalidomide 13. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs 14. Known SMAD-4 mutation, unless there has been a colonoscopy with normal (negative) results, or in which the patient has had no more than 5 small (in the opinion of the gastroenterologist) colonic polyps completely removed within the preceding 18 months 15. Anything that in the investigator's opinion is likely to interfere with completion of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epistaxis Severity Score | 12 months | Validated bleeding scale in HHT scored between 0-10, higher scores indicate worse bleeding |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum hemoglobin (g/dL) | 12 months | — |
| Hematologic Support Score | 12 months | Composite hematologic endpoint, higher scores indicate more hematologic support requirements |
| Intravenous iron infusion (mg elemental iron) | 12 months | — |
| Red cell transfusion (units of packed red blood cells) | 12 months | — |
| Incidence of treatment-emergent adverse events (safety) | 12 months | — |
Countries
United States
Contacts
STUDY_DIRECTOREllen Zhang, MD
Stanford University
Outcome results
None listed